Tsakalidis D, Pratsidou P, Hitoglou-Makedou A, Tzouvelekis G, Sofroniadis I
Second Department of Pediatrics, Aristotle University of Thessaloniki, Greece.
Pediatr Infect Dis J. 1992 Dec;11(12):1036-42. doi: 10.1097/00006454-199211120-00009.
This prospective study with an 18-month posttreatment follow-up evaluated the efficacy of intensive short course chemotherapy in Greek children with pulmonary or extrapulmonary tuberculosis. Between November, 1988, and March 1991 a 2-month regimen of rifampin, 10 to 12 mg/kg/day, isoniazid, 10 to 12 mg/kg/day, and pyrazinamide, 30 to 35 mg/kg/day, followed by rifampin and isoniazid for the remaining 4 months, was administered orally to 36 children with tuberculosis. Twenty-three boys and 13 girls ages 8 months to 12 years (mean, 5 1/2 years) were enrolled in the study. The diagnostic criteria for establishing tuberculosis were tuberculin skin test reactivity, radiographic findings compatible with tuberculosis, epidemiological data and clinical and laboratory findings. Four children had extrapulmonary and 32 had pulmonary tuberculosis; 9 of the latter were asymptomatic. Among the pulmonary cases there were 2 children with pleural effusion. Clinical response to therapy was apparent within 7 to 14 days; the pleural effusions resolved in 2 to 6 weeks and the pulmonary infiltrates cleared in 2 to 6 months. Hilar adenopathy regressed within 18 months or longer. No serious problems with drug tolerance or toxicity were noted during the treatment period. Temporary hyperuricemia and transient elevation in serum transaminases were observed in 11 patients but no drug modification was required. There were no posttreatment relapses. These findings suggest that intensive short course chemotherapy for the treatment of Greek children with pulmonary or extrapulmonary tuberculosis appears to be effective, safe, of good patient compliance and comparable to the longer treatment regimens.
这项前瞻性研究进行了18个月的治疗后随访,评估了强化短程化疗对希腊患肺结核或肺外结核儿童的疗效。在1988年11月至1991年3月期间,对36名结核病患儿口服了为期2个月的治疗方案,即利福平10至12毫克/千克/天、异烟肼10至12毫克/千克/天和吡嗪酰胺30至35毫克/千克/天,随后在剩余4个月给予利福平和异烟肼。研究纳入了23名男孩和13名女孩,年龄在8个月至12岁之间(平均5.5岁)。确立结核病的诊断标准为结核菌素皮肤试验反应性、与结核病相符的影像学表现、流行病学数据以及临床和实验室检查结果。4名儿童患有肺外结核,32名患有肺结核;后者中有9名无症状。在肺结核病例中,有2名儿童伴有胸腔积液。治疗7至14天内临床反应明显;胸腔积液在2至6周内消退,肺部浸润在2至6个月内清除。肺门淋巴结肿大在18个月或更长时间内消退。治疗期间未发现严重的药物耐受性或毒性问题。11名患者出现了暂时性高尿酸血症和血清转氨酶短暂升高,但无需调整药物。治疗后无复发情况。这些研究结果表明,强化短程化疗治疗希腊患肺结核或肺外结核的儿童似乎有效、安全,患者依从性良好,且与较长疗程的治疗方案相当。